Class information for:
Level 1: TRASTUZUMAB//LAPATINIB//PERTUZUMAB

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
2563 2207 44.0 84%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
317 3       HER2//TRASTUZUMAB//CHRONIC MYELOID LEUKEMIA 39408
652 2             HER2//TRASTUZUMAB//HER 2 NEU 13568
2563 1                   TRASTUZUMAB//LAPATINIB//PERTUZUMAB 2207

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 TRASTUZUMAB authKW 3309393 30% 36% 670
2 LAPATINIB authKW 1560046 12% 44% 254
3 PERTUZUMAB authKW 1096183 5% 70% 114
4 HER2 authKW 856202 18% 15% 403
5 HER2 POSITIVE authKW 687545 4% 61% 81
6 METASTATIC BREAST CANCER authKW 325182 9% 12% 193
7 NERATINIB authKW 303655 1% 73% 30
8 T DM1 authKW 262134 2% 56% 34
9 TRASTUZUMAB RESISTANCE authKW 245998 2% 52% 34
10 TRASTUZUMAB EMTANSINE authKW 183341 1% 51% 26

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Oncology 52518 78% 0% 1727
2 Obstetrics & Gynecology 525 5% 0% 120
3 Pharmacology & Pharmacy 487 11% 0% 246
4 Cell Biology 161 6% 0% 143
5 Medicine, Research & Experimental 53 3% 0% 68
6 Health Policy & Services 29 1% 0% 19
7 Health Care Sciences & Services 26 1% 0% 26
8 Medicine, General & Internal 14 3% 0% 67
9 Genetics & Heredity 4 2% 0% 47
10 Biotechnology & Applied Microbiology 2 2% 0% 46

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MED DEV ONCOL 52137 0% 54% 7
2 ONCOL MED DEV 49178 0% 44% 8
3 BREAST MED ONCOL 47561 3% 5% 69
4 ARIZONA ONCOL 44267 0% 80% 4
5 MED ONCOL 40600 17% 1% 370
6 ANAT PATOL BIOREN 36888 0% 67% 4
7 JULES BORDET 33382 2% 5% 47
8 BREAST DATA 30417 0% 20% 11
9 WASHINGTON CANC 29434 1% 10% 21
10 BREAST CANC GYNECOL CANC 27668 0% 100% 2

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CLINICAL BREAST CANCER 56458 3% 7% 56
2 BREAST CARE 31387 2% 6% 36
3 ONCOLOGIST 18173 2% 2% 54
4 BREAST CANCER RESEARCH AND TREATMENT 15379 4% 1% 90
5 ANNALS OF ONCOLOGY 14138 4% 1% 92
6 JOURNAL OF CLINICAL ONCOLOGY 11770 5% 1% 118
7 BREAST 10512 2% 2% 43
8 BREAST CANCER RESEARCH 8199 2% 2% 36
9 EJC SUPPLEMENTS 7213 1% 4% 13
10 CANCER TREATMENT REVIEWS 5538 1% 1% 28

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 TRASTUZUMAB 3309393 30% 36% 670 Search TRASTUZUMAB Search TRASTUZUMAB
2 LAPATINIB 1560046 12% 44% 254 Search LAPATINIB Search LAPATINIB
3 PERTUZUMAB 1096183 5% 70% 114 Search PERTUZUMAB Search PERTUZUMAB
4 HER2 856202 18% 15% 403 Search HER2 Search HER2
5 HER2 POSITIVE 687545 4% 61% 81 Search HER2+POSITIVE Search HER2+POSITIVE
6 METASTATIC BREAST CANCER 325182 9% 12% 193 Search METASTATIC+BREAST+CANCER Search METASTATIC+BREAST+CANCER
7 NERATINIB 303655 1% 73% 30 Search NERATINIB Search NERATINIB
8 T DM1 262134 2% 56% 34 Search T+DM1 Search T+DM1
9 TRASTUZUMAB RESISTANCE 245998 2% 52% 34 Search TRASTUZUMAB+RESISTANCE Search TRASTUZUMAB+RESISTANCE
10 TRASTUZUMAB EMTANSINE 183341 1% 51% 26 Search TRASTUZUMAB+EMTANSINE Search TRASTUZUMAB+EMTANSINE

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 ARTEAGA, CL , SLIWKOWSKI, MX , OSBORNE, CK , PEREZ, EA , PUGLISI, F , GIANNI, L , (2012) TREATMENT OF HER2-POSITIVE BREAST CANCER: CURRENT STATUS AND FUTURE PERSPECTIVES.NATURE REVIEWS CLINICAL ONCOLOGY. VOL. 9. ISSUE 1. P. 16 -32 71 57% 276
2 RIMAWI, MF , SCHIFF, R , OSBORNE, CK , (2015) TARGETING HER2 FOR THE TREATMENT OF BREAST CANCER.ANNUAL REVIEW OF MEDICINE, VOL 66. VOL. 66. ISSUE . P. 111 -128 63 77% 26
3 NIELSEN, DL , ANDERSSON, M , KAMBY, C , (2009) HER2-TARGETED THERAPY IN BREAST CANCER. MONOCLONAL ANTIBODIES AND TYROSINE KINASE INHIBITORS.CANCER TREATMENT REVIEWS. VOL. 35. ISSUE 2. P. 121-136 91 65% 54
4 THERY, JC , LLORCA, FP , RAYMOND, E , AZRIA, D , SPANO, JP , (2014) RESISTANCE TO HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR TYPE 2-TARGETED THERAPIES.EUROPEAN JOURNAL OF CANCER. VOL. 50. ISSUE 5. P. 892-901 61 81% 22
5 SWAIN, SM , BASELGA, J , KIM, SB , RO, J , SEMIGLAZOV, V , CAMPONE, M , CIRUELOS, E , FERRERO, JM , SCHNEEWEISS, A , HEESON, S , ET AL (2015) PERTUZUMAB, TRASTUZUMAB, AND DOCETAXEL IN HER2-POSITIVE METASTATIC BREAST CANCER.NEW ENGLAND JOURNAL OF MEDICINE. VOL. 372. ISSUE 8. P. 724 -734 22 92% 185
6 MENYHART, O , SANTARPIA, L , GYORFFY, B , (2015) A COMPREHENSIVE OUTLINE OF TRASTUZUMAB RESISTANCE BIOMARKERS IN HER2 OVEREXPRESSING BREAST CANCER.CURRENT CANCER DRUG TARGETS. VOL. 15. ISSUE 8. P. 665 -683 93 56% 1
7 WILKS, ST , (2015) POTENTIAL OF OVERCOMING RESISTANCE TO HER2-TARGETED THERAPIES THROUGH THE PI3K/AKT/MTOR PATHWAY.BREAST. VOL. 24. ISSUE 5. P. 548 -555 59 78% 8
8 PUGLISI, F , MINISINI, AM , DE ANGELIS, C , ARPINO, G , (2012) OVERCOMING TREATMENT RESISTANCE IN HER2-POSITIVE BREAST CANCER POTENTIAL STRATEGIES.DRUGS. VOL. 72. ISSUE 9. P. 1175 -1193 76 67% 13
9 FABI, A , MOTTOLESE, M , SEGATTO, O , (2014) THERAPEUTIC TARGETING OF ERBB2 IN BREAST CANCER: UNDERSTANDING RESISTANCE IN THE LABORATORY AND COMBATING IT IN THE CLINIC.JOURNAL OF MOLECULAR MEDICINE-JMM. VOL. 92. ISSUE 7. P. 681 -695 82 58% 8
10 HURVITZ, SA , HU, YF , O'BRIEN, N , FINN, RS , (2013) CURRENT APPROACHES AND FUTURE DIRECTIONS IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER.CANCER TREATMENT REVIEWS. VOL. 39. ISSUE 3. P. 219 -229 64 63% 49

Classes with closest relation at Level 1


Rank Class id link
1 6321 HER2//HER 2 NEU//TOP2A
2 5180 C ERBB 2//HER 2 NEU//P185
3 13462 HER2//GASTRIC CANCER//HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
4 4433 NEUREGULIN//NEUREGULIN 1//ERBB4
5 4400 CARDIOTOXICITY//ANTHRACYCLINES//CARDIO ONCOLOGY
6 35026 M1B PROSTATE CANCER//BIOMARKER EPIDERMAL GROWTH FACTOR RECEPTOR EGFR//C ERB B 2 NEU GENE
7 16780 CANC VACCINE DEV PROGRAM//CANC IMMUNOL IMMUNOTHER Y//TUMOR VACCINE GRP
8 7620 FULVESTRANT//ENDOCRINE RESISTANCE//FASLODEX
9 17657 BEVACIZUMAB//METASTATIC BREAST CANCER//APATINIB
10 3339 NEOADJUVANT CHEMOTHERAPY//LOCALLY ADVANCED BREAST CANCER//PATHOLOGIC COMPLETE RESPONSE

Go to start page